Glaukos' iDose TR Shows Stronger IOP Reduction in Glaucoma Trial

  • Glaukos' Phase 4 trial showed iDose TR reduced mean diurnal IOP by 11.1 mmHg when combined with cataract surgery, compared to 7.4 mmHg with surgery alone.
  • The study achieved statistical significance (p<0.0001) with a clinically meaningful incremental treatment effect of 3.6 mmHg.
  • iDose TR demonstrated a favorable safety profile with no treatment-related adverse events of corneal endothelial cell loss or cystoid macular edema.
  • The trial randomized 149 study eyes, with 74 assigned to the iDose TR group and 75 to the control group.

Glaukos' positive Phase 4 trial results for iDose TR reinforce its position in the glaucoma treatment landscape. The study's success highlights the potential for procedural pharmaceuticals to address patient non-compliance issues with topical medications. This aligns with broader industry trends toward long-duration, intracameral therapies that improve treatment adherence and outcomes for chronic eye diseases.

Market Adoption
How quickly iDose TR can gain traction in combination with cataract surgery, expanding its use beyond standalone procedures.
Regulatory Dynamics
Whether the positive Phase 4 results will accelerate regulatory approvals or expand indications for iDose TR.
Competitive Positioning
The pace at which Glaukos can differentiate iDose TR from existing glaucoma treatments and topical medications.